Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 180.05
- Piotroski Score 1.00
- Grade N/A
- Symbol (ESLA)
- Company Estrella Immunopharma, Inc.
- Price $1.28
- Changes Percentage (10.35%)
- Change $0.12
- Day Low $1.11
- Day High $1.34
- Year High $3.50
Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/18/2024
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.27
- Trailing P/E Ratio -3.33
- Forward P/E Ratio -3.33
- P/E Growth -3.33
- Net Income $-7,311,723
Income Statement
Quarterly
Annual
Latest News of ESLA
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Tesla stock: What will it take to turn Elon Musk's DREAMS into reality?
Morgan Stanley believes Tesla's AI potential is key to its long-term success. The investment bank sees Gen AI and LLMs as crucial in unlocking Tesla's value. The shift from auto-centric focus to broad...
By Yahoo! Finance | 21 hours ago -
Why Tesla (TSLA) Outpaced the Stock Market Today
Tesla's stock closed at $261.63, up 0.45%, outperforming S&P 500. Analysts predict EPS at $0.58, a 12.12% drop, with revenue expected to rise by 10.44%....
By Yahoo! Finance | 1 day ago -
Tesla, Musk beat shareholder lawsuit over self-driving promises
Tesla and Elon Musk have won the dismissal of a lawsuit accusing them of defrauding shareholders by overstating self-driving technology safety. U.S. District Judge in San Francisco ruled that sharehol...
By Yahoo! Finance | 1 day ago